Sanofi Will Employ Adagene’s Technology For Precision Targeting In Cancer

 
• By Joseph Haas

Sanofi will pay $17.5m up front to license candidates developed with Adagene’s SAFEbody platform, which can mask antibodies, enabling them to reach cancer targets in the tumor microenvironment.

Tumor microenvironment
Adagene's technology masks antibodies until activated by the tumor microenvironment • Source: Alamy

More from Deals

More from Business